Roche: therapy cuts risk of lung cancer death.

(CercleFinance.com) - Roche said on Monday a late-stage clinical trial has showed that the combination of Tecentriq, Avastin and chemotherapy significantly reduced the risk of disease worsening or death in people with a certain type of advanced lung cancer.


The phase III study met its co-primary endpoint of progression-free survival and demonstrated that the treatment provided a meaningful reduction in the risk of the disease worsening, or death, compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC).

Still, Roche said that this data are not fully mature, with further analysis expected in the first half of 2018.

This Monday Roche also unveiled positive results from a phase III study evaluating Hemlibra in adults and adolescents with haemophilia A without inhibitors to factor VIII.

The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in the number of treated bleeds over time in people receiving Hemlibra prophylaxis every week compared to those receiving no prophylaxis.

Copyright (c) 2017 CercleFinance.com. All rights reserved.